Synaptogenix, Inc.

The momentum for this stock is not very good. Tradey thinks it is not wise to invest in Synaptogenix, Inc..
Log in to see more information.
SNPX Fundamental Data by TradingView

News

Synaptogenix Announces $5.0 Million Financing
Synaptogenix Announces $5.0 Million Financing

PR Newswire Synaptogenix Announces $5.0 Million Financing Synaptogenix Announces $5.0 Million Financing PR Newswire NEW YORK, Sept. 11, 2024 NEW YORK, Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq...\n more…

Synaptogenix (NASDAQ:SNPX) Shares Down 0.5%
Synaptogenix (NASDAQ:SNPX) Shares Down 0.5%

Zolmax Shares of Synaptogenix, Inc. (NASDAQ:SNPX - Get Free Report) were down 0.5% on Friday . The stock traded as low as $3.66 and last traded at $3.70. Approximately 6,582 shares changed hands during...\n more…

SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024
SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nSynaptogenix just reported results for the second quarter of 2024.\nThe post SNPX Stock Earnings: Synaptogenix Reported Results for Q2...\n more…

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

PR Newswire Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury Synaptogenix Announces New Collaboration with LSU Health New Orleans for...\n more…

Synaptogenix (NASDAQ:SNPX) Upgraded by Maxim Group to "Buy"
Synaptogenix (NASDAQ:SNPX) Upgraded by Maxim Group to "Buy"

Ticker Report Maxim Group upgraded shares of Synaptogenix (NASDAQ:SNPX - Free Report) from a hold rating to a buy rating in a research report released on Thursday morning, MarketBeat.com reports. They currently...\n more…

Synaptogenix (NASDAQ:SNPX) Lifted to Buy at Maxim Group
Synaptogenix (NASDAQ:SNPX) Lifted to Buy at Maxim Group

Zolmax Maxim Group upgraded shares of Synaptogenix (NASDAQ:SNPX - Free Report) from a hold rating to a buy rating in a research note released on Thursday morning, MarketBeat Ratings reports. The brokerage...\n more…